Grade @ or @ treatment-related adverse events occurred in @ % of the patients receiving nivolumab and in @ % of the patients receiving everolimus ; the most common event with nivolumab was fatigue ( in @ % of the patients ) , and the most common event with everolimus was anemia ( in @ % ) .